Acurx invites individual and institutional
investors, financial advisors and analysts to attend its real-time,
interactive presentation at the Emerging Growth Conference.
STATEN
ISLAND, N.Y., June 20,
2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.
(NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage
biopharmaceutical company developing a new class of antibiotics for
difficult-to-treat bacterial infections, announced today that
David P. Luci, President & CEO,
will present at the Emerging Growth Conference as follows:
Date:
|
Wednesday, July 12,
2023
|
Time:
|
12:35 p.m. Eastern
Time
|
Your unique link to register is:
https://goto.webcasts.com/starthere.jsp?ei=1603282&tp_key=1cd1dcc46a&sti=axcp
This pre-recorded online event will provide current stockholders
and the investment community the opportunity to receive an update
on Acurx Pharmaceuticals and its current initiatives.
The presentation will be webcast at the aforementioned time, and
archived for 30 days thereafter, via the Company's website at
www.acurxpharma.com, under the Investors section.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a clinical stage biopharmaceutical
company focused on developing new antibiotics for difficult to
treat infections. The Company's approach is to develop antibiotic
candidates that target the DNA polymerase IIIC enzyme and its
R&D
pipeline includes antibiotic product candidates that target Gram-positive bacteria, including
Clostridioides difficile, methicillin-resistant
Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus
(VRE) and drug-resistant Streptococcus pneumoniae (DRSP).
To learn more about Acurx
Pharmaceuticals and its product pipeline, please visit
www.acurxpharma.com.
Forward-Looking Statements
Any statements in this press release about our future
expectations, plans and prospects, including statements regarding
our strategy, future operations, prospects, plans and objectives,
and other statements containing the words "believes,"
"anticipates," "plans," "expects," and similar
expressions, constitute forward-looking statements within the meaning
of The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: whether ibezapolstat will benefit from the QIDP
designation; whether ibezapolstat will advance through the clinical
trial process on a timely basis; whether the results of the
clinical trials of ibezapolstat will warrant the submission of
applications for marketing approval, and if so, whether
ibezapolstat will receive approval from the FDA or equivalent
foreign regulatory agencies where approval is sought; whether, if
ibezapolstat obtains approval, it will be successfully distributed
and marketed; and other risks and uncertainties described in the
Company's annual report filed with the Securities and Exchange
Commission on Form 10-K for the year ended December 31, 2022, and in the Company's
subsequent filings with the Securities and Exchange Commission.
Such forward- looking statements speak only as of the date of this
press release, and Acurx disclaims any intent or obligation to
update these forward-looking statements to reflect events or
circumstances after the date of such statements, except as may be
required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci
President & CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original
content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-present-at-the-emerging-growth-conference-on-july-12-2023-301854520.html
SOURCE Acurx Pharmaceuticals, Inc.